amphotericin B

Also found in: Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.
Related to amphotericin B: liposomal amphotericin B

am·pho·ter·i·cin B

An antibiotic, C47H73NO17, derived from strains of the actinomycete Streptomyces nodosus and used to treat systemic fungal infections.


amphotericin B

n anfotericina B
References in periodicals archive ?
5) However, access to the preferred drugs, amphotericin B and flucytosine, is a challenge, as highlighted by a rapid survey of MSF HIV/AIDS programmes in 9 countries.
An article recently published on this topic in Dynamics, the Journal of the Canadian Association of Critical Care Nurses (entitled "ALERT: Mix-ups between conventional and lipid formulations of amphotericin B can be extremely dangerous.
Intravenous amphotericin is currently marketed in Canada as conventional (non-lipid) amphotericin B (Fungizone[R]) and as lipid formulations (AmBisome[R]--a liposomal formulation, and Abelcet[R]--a lipid complex formulation).
The aim of this study was to find an alternative for amphotericin B currently used in treatment of fungal infections.
To show comparable blood levels to existing commercial versions of Amphotericin B, which are administered via IV infusion, is exciting to us as there is a clear commercial medical need for an oral antifungal with the strength and breadth of action of Amphotericin.
These observations suggest that alterations in sample turbidity related to liposomal amphotericin B rather than increased triglyceride values may have contributed to the false increases of phosphorus values.
Current treatment guidelines, which advocate amphotericin B as induction therapy, are based on a large randomised controlled trial (RCT) from the USA that compared initial therapy with amphotericin B (0.
Amphotericin B exerts broad-spectrum coverage and remains the drug of choice for life-threatening invasive fungal infections.
Conventional amphotericin B deoxycholate has long been used, but is limited in efficacy and has significant toxicity.
Recent guidelines from the National Institute of Allergy and Infectious Diseases Mycoses Study Group and the Infectious Diseases Society of America suggest that life-threatening pulmonary or disseminated non-CNS disease, any CNS disease, and disease in the immunocompromised host be treated with amphotericin B to complete a total dose of 1.
We are delighted to be able to commercialize the unique, patented BDSI nanocochleate delivery technology using amphotericin B for the indication of chronic rhinosinusitis.
A February 2010 Indian study published in The New England Journal of Medicine found that a single dose of AmBisome 10mg/kg is safe, effective and significantly less expensive than the 15 infusions of amphotericin B deoxycholate over the course of a 29-day hospitalization.